Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Depreciation & Amortization (CF) (2019 - 2025)

Historic Depreciation & Amortization (CF) for Revolution Medicines (RVMD) over the last 7 years, with Q3 2025 value amounting to $2.1 million.

  • Revolution Medicines' Depreciation & Amortization (CF) rose 2563.95% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.2 million, marking a year-over-year increase of 1835.4%. This contributed to the annual value of $6.6 million for FY2024, which is 3008.73% up from last year.
  • According to the latest figures from Q3 2025, Revolution Medicines' Depreciation & Amortization (CF) is $2.1 million, which was up 2563.95% from $1.8 million recorded in Q2 2025.
  • Revolution Medicines' Depreciation & Amortization (CF)'s 5-year high stood at $2.1 million during Q3 2025, with a 5-year trough of $671000.0 in Q1 2021.
  • In the last 5 years, Revolution Medicines' Depreciation & Amortization (CF) had a median value of $1.2 million in 2023 and averaged $1.3 million.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first skyrocketed by 617.09% in 2021, then soared by 3793.52% in 2022.
  • Over the past 5 years, Revolution Medicines' Depreciation & Amortization (CF) (Quarter) stood at $833000.0 in 2021, then soared by 37.94% to $1.1 million in 2022, then grew by 13.14% to $1.3 million in 2023, then surged by 33.46% to $1.7 million in 2024, then grew by 18.9% to $2.1 million in 2025.
  • Its Depreciation & Amortization (CF) stands at $2.1 million for Q3 2025, versus $1.8 million for Q2 2025 and $1.7 million for Q1 2025.